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The presented article describes data from secondary analyses,
related to the research article entitled “Cannabis consumption and
Non-Alcoholic Fatty Liver Disease. A three years longitudinal study
in first episode non-affective psychosis patients” [1]. We present
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We present in this article data derived from secondary analyses of a previous study on the relation
between cannabis consumption and NAFLD in a Spanish cohort of drug-naïve patients with a first
episode of non-affective psychosis [1]. Raw data has been made accessible through the public data
repository “Mendeley Data” at https://doi.org/10.17632/hwn48wt7j6.1.
Table 1 describes some of the main clinical and socio-demographic characteristics of the global
study sample and of each cannabis groups (consumers and no consumers).
Table 2 describes the baseline and 3-years liver function tests differences between groups (cannabis
users vs non users), after having excluded those patients with a moderate-severe alcohol consumption.
Table 3 shows the longitudinal differences in liver function tests between groups (cannabis users,
discontinuers, non-users), after having excluded those patients with a moderate-severe alcohol
consumption.
Table 1
Baseline sociodemographic and clinical characteristics.
Cannabis users No cannabis users Total Statsa
Mean (SD) Mean (SD) Mean (SD) df F P
Age at admission, years 25.2 (6.0) 33.7 (9.9) 30.4 (9.5) 1; 389 90.59 < 0.001
DUP, months 7.3 (10.3) 16.3 (36.7) 12.8 (29.7) 1; 386 8.56 0.004
DUI, months 18.1 (21.49) 26.3 (45.25) 23.98 (37.86) 1; 376 4.22 0.041
SANS-SAPS at inclusion 21.4 (7.6) 19.6 (7.6) 20.3 (7.7) 1; 388 5.24 0.023
Initial antipsychotic doses b 215.3 (86.4) 206.0 (82.8) 209.6 (84.2) 1; 389 1.13 0.289
% (N) % (N) % (N) N X2 P
Sex, males 80.0 (120) 40.4 (97) 55.6 (217) 390 58.60 < 0.001
Education level, secondary or lower 58.7 (88) 37.5 (90) 45.6 (178) 390 16.67 < 0.001
Family socioeconomic status, Not/Low qualified 52.0 (78) 49.8 (119) 50.6 (197) 389 0.18 0.375
Unmarried 88.0 (132) 65.0 (156) 73.8 (288) 390 25.28 < 0.001
Living with family 72.7 (109) 74.2 (178) 73.6 (287) 390 0.11 0.416
Student
Unemployed 45.3 (68) 39.2 (94) 41.5 (162) 390 1.45 0.136
Diagnosis, schizophrenia 54.5 (81) 50.8 (121) 52.2 (202) 387 4.70 0.453
Hospitalization at inclusion 72.0 (108) 65.3 (156) 67.9 (264) 389 1.91 0.101
Drug consumption
Tobacco smoking, yes 88.7 (133) 37.5 (90) 57.2 (223) 390 98.70 < 0.001
Alcohol consumption, yes 85.2 (127) 29.3 (70) 50.8 (197) 388 114.94 < 0.001
Hazardous alcohol consumption, yes c 4.9 (19) 2.8 (11) 7.7 (30) 388 0.152 0.435
Concomitant treatments
Anticholinergics, baseline 4.7 (7) 3.3 (8) 3.9 (15) 389 0.462 0.336
Hypnotics, baseline 33.6 (50) 28.9 (69) 30.7 (119) 388 0.95 0.195
Benzodiazepines, baseline 66.4 (99) 58.2 (139) 61.3 (238) 388 2.66 0.064
Antidepressants, baseline 1.3 (2) 1.7 (4) 1.5 (6) 388 0.07 0.578
Mood stabilizers, baseline 0 (0) 0.4 (1) 0.3 (1) 387 0.63 0.615
a Statistical analyses: Un-adjusted analysis of variance (ANOVA) for continuous variables and chi-square test for categorical
variables. Abbreviations: DUP: Duration of untreated psychosis. DUI: Duration of untreated illness. SANS: Scale for the
Assessment of Negative Symptoms. SAPS: Scale for the Assessment of Positive Symptoms.
b Equivalent doses of antipsychotic medication following Gardner et al., 2010 criteria.
c Alcohol consumption thresholds for the diagnosis of NAFLD: 140 and 210 g of alcohol per week in women and men,
respectively (Leoni et al., 2018).
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excluded those patients with a moderate-severe alcohol consumption.
2. Experimental design, materials and methods
2.1. Population description
To obtain the present data, we included adult patients presenting a first episode of non-affective
psychosis between 2001 and 2015 (full description of inclusion criteria in Pelayo et al., 2008), for
whom we had information of cannabis use (yes/no) both at baseline and at 3-years follow-up [2].
Patients were evaluated at baseline and periodically thereafter until year 3. Anthropometric measures
and fasting blood samples for lipid, glycemic and liver determinations, were collected. Main NAFLD and
liver fibrosis scores (FLI, FIB-4 and NAFLD fibrosis scores) were calculated accordingly to previous
literature [3e5]. Cannabis and other drugs were recorded from patients self-reports.
Table 1 shows the main clinical and socio-demographic characteristics of the study sample, and of
each consuming groups (cannabis users and no users), at study entry. It also contains the results from
the statistical analyses comparing these two groups regarding their clinical and sociodemographic
characteristics. Patients reporting cannabis consumption were significantly younger than the non-
consumers. They also presented a shorter duration of untreated psychosis, and more severe psy-
chotic symptomatology at study entry. More patients among the cannabis group reported smoking
tobacco and drinking alcohol than in the no-cannabis group.
Table 2
Baseline and 3-years liver function tests in first episode psychosis, excluding patients with severe alcohol consumption.
Baseline 3-years
Cannabis users No cannabis users Statsa Cannabis users No cannabis users Statsa
Mean (SE) Mean (SE) df F P Mean (SE) Mean (SE) df F P
FLI algorithm factors
BMI (kg/m2) 21.9 (0.4) 24.0 (0.3) 1; 342 12.585 <0.001 24.1 (0.9) 27.3 (0.3) 1; 334 10.049 0.002
Waist circumference (cm) 81.6 (1.7) 84.3 (1.1) 1; 180 1.346 0.247 78.7 (3.3) 91.2 (0.9) 1; 207 12.912 <0.001
Triglycerides 83.5 (4.5) 79.3 (2.9) 1; 282 0.512 0.475 85.3 (11.9) 110.9 (3.5) 1; 333 4.158 0.042
Liver laboratory tests
AST 23.5 (2.1) 27.8 (1.3) 1; 313 2.375 0.124 24.3 (1.9) 24.4 (0.6) 1; 334 0.001 0.973
ALT 21.8 (2.9) 28.9 (1.9) 1; 335 3.205 0.074 26.3 (3.9) 29.9 (1.2) 1; 335 0.753 0.386
GGT 29.2 (4.9) 15.7 (3.2) 1; 316 4.276 0.039 26.1 (9.4) 27.0 (2.8) 1; 334 0.008 0.930
AP 83.3 (9.6) 92.0 (7.2) 1; 123 0.417 0.520 66.2 (5.5) 65.6 (1.9) 1; 125 0.010 0.920
Bilirubin 0.71 (0.09) 0.80 (0.07) 1; 103 0.513 0.476 0.68 (0.09) 0.59 (0.03) 1; 122 0.863 0.355
Albumin 4.54 (0.04) 4.54 (0.03) 1; 305 0.006 0.939 4.54 (0.05) 4.53 (0.01) 1; 322 0.039 0.844
Other laboratory tests
Platelets 250.4 (7.9) 249.6 (5.1) 1; 267 0.005 0.941 252.5 (12.5) 243.7 (3.9) 1; 321 0.437 0.509
Leptin 6.6 (1.1) 9.5 (0.7) 1; 264 3.680 0.056 10.0 (2.2) 14.8 (0.6) 1; 324 4.274 0.040
hsCRP 0.17 (0.09) 0.16 (0.06) 1; 154 0.009 0.926 0.14 (0.12) 0.29 (0.03) 1; 201 1.495 0.223
Hepatic disease indexes
FLI 15.8 (3.5) 18.8 (2.2) 1; 153 0.432 0.512 7.4 (7.9) 38.6 (2.1) 1; 202 14.169 <0.001
FIB-4 score 0.69 (0.05) 0.68 (0.03) 1; 250 0.031 0.876 0.73 (0.05) 0.69 (0.01) 1; 318 0.738 0.391
NAFDL score 3.54 (0.14) 3.41 (0.09) 1; 242 0.508 0.477 3.35 (0.19) 3.05 (0.06) 1; 311 2.277 0.132
Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase;
hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score.














Longitudinal differences in liver function tests, after 3 years of antipsychotic treatment, excluding patients with severe alcohol consumption.
Cannabis users Discontinuers Non-users Statisticsa
Mean diff (SE) Mean diff (SE) Mean diff (SE) df F P
FLI algorithm factors
BMI (kg/m2) 3.0 (0.7) 4.5 (0.4) 3.6 (0.2) 2; 331 2.791 0.063
Waist circumference (cm) 2.4 (2.8) 7.3 (1.8) 7.2 (1.0) 2; 171 1.336 0.266
Triglycerides 7.8 (12.2) 27.0 (7.5) 35.7 (4.4) 2; 272 2.118 0.122
Other liver laboratory tests
AST 0.89 (4.03) 0.91 (2.56) 3.34 (1.45) 2; 303 0.522 0.594
ALT 6.5 (5.7) 5.7 (3.5) 1.7 (2.1) 2; 325 0.499 0.608
GGT 7.3 (6.6) 7.5 (4.2) 7.2 (2.5) 2; 306 0.002 0.998
AP 5.4 (16.3) 18.2 (10.3) 30.4 (7.2) (6.5) 2; 121 0.902 0.409
Bilirubin 0.26 (0.11) 0.03 (0.08) 0.22 (0.05) 2; 98 2.556 0.083
Albumin 0.001 (0.09) 0.020 (0.05) 0.028 (0.03) 2; 259 0.040 0.961
Other laboratory tests
Platelets 10.3 (11.9) 1.2 (7.1) 13.4 (4.2) 2; 254 1.473 0.231
Leptin 4.6 (2.7) 7.1 (1.6) 5.4 (0.9) 2; 247 0.563 0.570
hsCRP 0.005 (0.22) 0.060 (0.12) 0.102 (0.07) 2; 145 0.115 0.892
Hepatic disease indexes
FLI 3.7 (6.6) 19.6 (4.2) 19.8 (2.3) 2; 144 5.826 0.004
FIB-4 score 0.022 (0.09) 0.035 (0.05) 0.047 (0.03) 2; 237 0.803 0.449
NAFDL score 0.21 (0.23) 0.38 (0.15) 0.58 (0.08) 2; 224 1.274 0.282
Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase;
hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score.
a ANCOVAmodel: mean differences after 3 years of treatment were used as dependent variables, evolution of cannabis use was the fixed factor and age, sex, and tobacco and alcohol use














Comparison of proportion of subjects with pathological liver functions tests, at baseline and at 3-years in each cannabis consumption group, excluding patients with severe alcohol
consumption.
3 year follow-up Baseline % difference N pa
% (n) % (n)
AST, > 35 UI/L
Continuer 6.9 (2) 13.8 (4) 6.9 29 0.687
Discontinuers 9.7 (7) 15.3 (11) 5.6 72 0.424
Non-users 7.8 (16) 14.6 (30) 6.8 206 0.044
Total 8.1 (25) 14.7 (45) 6.6 307 0.015
ALT, > 40 UI/L
Continuer 16.7 (5) 10.0 (3) 6.7 30 0.625
Discontinuers 22.0 (18) 8.5 (7) 13.5 82 0.019
Non-users 16.6 (36) 12.4 (27) 4.2 217 0.253
Total 17.9 (59) 11.2 (37) 6.7 329 0.013
GGT, > 32 UI/L
Continuer 10.0 (3) 0 10.0 30 e
Discontinuers 23.0 (17) 6.8 (5) 16.2 74 0.002
Non-users 19.9 (41) 10.7 (22) 9.2 206 0.001
Total 19.7 (61) 8.7 (27) 11.0 310 <0.001
Leptin, > 10 ng/ml
Continuer 10.0 (2) 0 10.0 20 e
Discontinuers 42.6 (26) 13.1 (8) 29.5 61 <0.001
Non-users 64.5 (109) 36.1 (61) 28.4 169 <0.001
Total 54.8 (137) 27.6 (69) 27.2 250 <0.001
hsCRP, > 0.3 ng/dL
Continuer 0 11.1 (1) 11.1 9 e
Discontinuers 20.5 (8) 7.7 (3) 12.8 39 0.125
Non-users 24.2 (24) 7.1 (7) 17.3 99 0.001
Total 21.8 (32) 7.5 (11) 14.3 147 <0.001
FLI,  60
Continuer 0 0 0 12 e
Discontinuers 28.1 (9) 6.2 (2) 21.9 32 0.022
Non-users 25.0 (25) 9.0 (9) 16.0 100 <0.001
Total 23.6 (34) 7.6 (11) 16.0 144 <0.001
Abbreviations: FLI, fatty liver Index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; hsCRP, high sensitivity C-reactive protein.
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Due to the well-known deleterious effect of alcohol on liver, and despite being one of the study's
exclusion criteria presenting an alcohol dependence, we considered appropriate carrying secondary
analyses after exclusion of those patients with alcohol consumption qualifying for moderate-severe
drinking. For this, moderate-severe alcohol use was defined using the accepted alcohol consumption
thresholds for the diagnosis of NAFLD: 140 and 210 g of alcohol per week in women and men,
respectively [6]. Tables 2e4 contains the results from the statistical analyses, both cross-sectional and
longitudinal, after excluding these patients (n ¼ 40).
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